|

More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

ByPsychedelic Spotlight

Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.

We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.

So what else can MindMed and MMED/MMEDF investors expect this year?

1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price

2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?

3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary

Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Similar Posts

  • MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ]

    Listen, Videos

    MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
    (MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.

    In this episode, we’ll cover several things.

    1.What happened?
    2.My general thoughts on the leadership change.
    3.My thoughts on JR Rahn’s successes and his departure.
    4.What Robert Barrow brings to the table as CEO.

    Links:
    MindMed changes leadership:
    https://mindmed.co/news/press-release/mindmed-announces-chief-executive-officer-transition/

    Robert Barrow background:
    https://mindmed.co/team/robert-barrow-1/
    https://www.newswire.ca/news-releases/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience-862550304.html

    General Reddit sentiment about MindMed’s leadership change:
    https://www.reddit.com/r/MindMedInvestorsClub/comments/nvwtou/expected_this_sub_to_be_on_fire_this_morning_but/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MNMD #MindmedNews

  • MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)

    Listen, Videos

    MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
    Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
    Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
    For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #mindmed #mmed #mnmdstock

  • Can DMT Treat Depression?

    Learn, Videos

    Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief Scientific and Chief Medical Officer of Small Pharma (TSX.V: DMT, OTC: DMTTF). Dr. Carol Routhledge is an expert in psychedelic medicines, and she specializes in DMT.

    In this interview, we attempted to answer the following questions:

    What happens when you take DMT?

    Can DMT help with depression?

    Is DMT safe?

    Small Pharma is a company that I am very excited about, as they are focussing on the psychedelic DMT, which I believe to have unlimited potential as a mental health drug.

    Small Pharma is currently running a phase 2 Clinical Trial Attempting to treat Major Depressive Disorder using DMT, the world’s furthest progress DMT Study. We can expect results by the end of the year. If they are successful, the company will begin a phase 3 trial.

    #DMT #SmallPharma #depression

  • Interview with Dr. Erica Zelfand

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.